^
Association details:
| Biomarker: | ALK positive + ALK L1196M + ALK D1203N |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC
Published date:
06/02/2023
Excerpt:
In six patients in which blood samples had been taken after lorlatinib resistance, ALK compound mutations were found in three patients (50%), which were G1202R/L1196M, L1196M/D1203N, and G1202R/F1174C.
DOI:
https://doi.org/10.1111/1759-7714.14980
